ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Will Acquire Drug Firm Excaliard

by Michael McCoy
November 28, 2011 | APPEARED IN VOLUME 89, ISSUE 48

Pfizer will pay an undisclosed sum to acquire Excaliard Pharmaceuticals, a San Diego-based firm that develops drugs for the treatment of skin fibrosis, also known as skin scarring. Excaliard’s lead product, EXC 001, is an antisense oligonucleotide in Phase II clinical trials. It works by inhibiting expression of connective tissue growth factor. EXC 001 was codiscovered by Excaliard and Isis Pharmaceuticals, which could receive up to $14 million from Pfizer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment